Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry: An Eastern Cooperative Oncology Group study (2192)

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 24, Issue 1, 2001, Pages 10-18

  Page, David L ^a,i   Gray, Robert ^b   Allred, D Craig ^c   Dressler, Lynn G ^d   Hatfield, Alan K ^e   Martino, Silvana ^f   Robert, Nicholas J ^g   Wood, William C ^h  

^a VANDERBILT UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e Carle Cancer Center CCOP   (United States)

^f The Breast Center Inc   (United States)

^g INOVA FAIRFAX HOSPITAL   (United States)

^h EMORY UNIVERSITY   (United States)

ⁱ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Flow cytometry; Histologic grading; S phase analysis

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CELL CYCLE S PHASE; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MITOSIS INDEX; OUTCOMES RESEARCH; PREDICTION; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MEDICAL FUTILITY; METHOTREXATE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PREDNISONE; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; S PHASE; SURVIVAL RATE;

EID: 0035114079     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200102000-00002     Document Type: Article

References (68)

1. Mitosis counting in tumors
2. The importance of histologic grade in long-term prognosis of breast cancer: A study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy
3. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up
4. ABC of breast diseases: Prognostic factors
5. Histologic grading of breast cancer. Let's do it
6. The histologic grading of cancer
7. Prognostic factors in early breast carcinoma
8. Integrating prognostic factors
9. Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: Preliminary analysis of an intergroup study (INT 0076)
10. A proposed classification of breast cancer based on kinetic information
11. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival
12. Prognostic factors in NSABP studies of women with node-negative breast cancer. National Surgical Adjuvant Breast and Bowel Project
13. Consensus statement: Treatment of early-stage breast cancer. National Institutes of Health Consensus Development Panel
14. Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer
15. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma
16. Integration of risk factors to allow patient selection for adjuvant systemic therapy in lymph node-negative breast cancer patients
17. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
18. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR): An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas
19. The Nottingham Prognostic Index in primary breast cancer
20. Prognostic value of histopathology in the breast
21. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors
22. Recommendations for the reporting of breast carcinoma, association of directors of anatomic and surgical pathology
23. Efficacy of adjuvant chemotherapy in high risk node negative breast cancer; an intergroup study (NT 0011)
24. Adjuvant therapy of node-negative breast cancer. Is it necessary for all patients?
25. Method for grading breast cancer
26. Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients
27. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer
28. Nonparametric estimation from incomplete observations
29. Evaluation of survival data and two new rank order statistics arising in its consideration
30. Regression models and life-tables
31. Survival and prognostic factors in node-negative breast cancer: Results of long-term follow-up studies
32. Tumor marker utility grading system
33. Results of the National Cancer Institute early breast cancer trial
34. Reporting and interpreting adjuvant therapy clinical trials
35. Classical prognostic factors in node-negative breast cancer: The DBCG experience
36. Confirmation of a prognostic index in primary breast cancer
37. Grading of invasive carcinoma of the breast
38. Assessment of histological grade
39. Reproducibility of pathological grading in breast cancer
40. Histologic grading of breast carcinoma: A reproducibility study
41. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson grading scheme for infiltrating ductal carcinoma
42. Histological grading of breast carcinomas: A study of interobserver agreement
43. Breast carcinoma in women under the age of 50: Relationship between p53 immunostaining, tumour grade, and axillary lymph node status
44. Early-onset breast cancer-histopathological and prognostic considerations
45. Bcl-2 and p53 expression in node-negative breast carcinoma: A study with long-term follow-up
46. DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer
47. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: Associations with other prognostic factors and survival
48. The prognostic effect of histological tumor grade in node-negative breast cancer patients
49. Intratumoral heterogeneity of proliferation in invasive breast carcinoma evaluated with MIB1 antibody
50. Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer
51. Treatment decisions in axillary node-negative breast cancer patients
52. International consensus panel on the treatment of primary breast cancer
53. Prognostic value of p53 in breast invasive ductal carcinoma
54. Pathologic predictors of tumor response to preoperative chemotherapy in locally advanced breast carcinoma
55. Proliferative rate by S-phase measurement may affect cure of breast cancer
56. Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: A prospective study
57. Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma
58. Construction and validation of a practical prognostic index for patients with metastatic breast cancer
59. The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy
60. Prognosis following local recurrence in the conservatively treated breast cancer patient
61. Prognostic factors in primary breast carcinoma
62. The Nottingham Prognostic Index in primary breast cancer
63. Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: Major importance of the mitotic count as a component of both grading systems
64. Premalignant and malignant disease of the breast: The roles of the pathologist
65. Status of breast cancer prognostication based on histopathologic data